Sequence Therapy in Patients with Metastatic Renal Cell Carcinoma: Comparison of Common Targeted Treatment Options Following Failure of Receptor Tyrosine Kinase Inhibitors

By: Jonas Buscha , Christoph Seidelb , Carsten Kempkensteffena, Manfred Johannsena, Ingmar Wolffa, Stefan Hinza, Ahmed Maghelia, Kurt Millera, Viktor Grünwaldb and Steffen Weikerta lowast

Published online: 01 December 2011

Keywords: Metastasis, Renal cell carcinoma, Tyrosine kinase inhibitor, Progressive disease

Abstract Full Text Full Text PDF (518 KB)



The best sequence of targeted therapy in patients with metastatic renal cell carcinoma (mRCC) has not been sufficiently defined.


To describe the efficacy and toxicity of sequential everolimus (EV) versus receptor tyrosine kinase inhibitor (rTKI) following failure of first rTKI treatment.

Design, setting, and participants

Retrospective study of 108 patients receiving rTKI or EV after progression on rTKI therapy at two German academic centres.


Sequence of systemic targeted treatment with sunitinib (n=85) or sorafenib (n=23) followed by EV (n=62) or another rTKI (n=46; sorafenib, n=35; sunitinib, n=11).


We measured response rate (Response Evaluation Criteria in Solid Tumours 1.0) and toxicity. Survival analysis (Kaplan-Meier method and Cox regression) was conducted for progression-free survival (PFS) and overall survival (OS).

Results and limitations

Main patient characteristics did not significantly differ by sequence of treatment groups (rTKI-rTKI vs rTKI-EV). Response rate following first rTKI failure was not significantly different between sequential therapies with a disease control rate of 51.6% (EV) and 43.5% (rTKI). The corresponding median PFS was 3.6 mo (95% confidence interval [CI], 1.8–5.4) for EV and 4.0 mo (3.2–4.9) for rTKI treatment. The estimated OS was longer for the rTKI-EV group (43 mo; 95% CI, 33.9–52.1) than for the rTKI-rTKI group (29 mo; 95% CI, 18.6–39.5; p=0.03), but this difference lost statistical significance in multivariable-adjusted analyses. Intrinsic rTKI resistance was independently associated with inferior subsequent PFS (hazard ratio [HR]: 1.79; 95% CI, 1.15–3.62; p=0.015) and OS (HR: 6.54; 95% CI, 3.01–14.20; p<0.001). Limitations are the retrospective design, limited numbers of cases, and residual confounding factors.


The sequence therapies rTKI-EV and rTKI-rTKI may be equally efficacious in terms of PFS and response rate, whereas a tendency towards superior survival was observed for the rTKI-EV sequence. These data, particularly the potential benefit of an early change of mode of action, need confirmation in randomised comparative trials.

Take Home Message

Sequential treatment with everolimus or another receptor tyrosine kinase inhibitor (rTKI) may be equally efficacious in terms of progression-free survival and response rate. Randomised comparative trials are needed to better define the treatment algorithms in rTKI-resistant disease.

Keywords: Metastasis, Renal cell carcinoma, Tyrosine kinase inhibitor, Progressive disease.

1. Introduction

During the last few years, efficacious therapeutic options have been developed for patients with metastatic renal cell carcinoma (mRCC). Most patients are treated with receptor tyrosine kinase inhibitors (rTKIs), particularly sunitinib (Sun), based on the results obtained in two meta-analyses [1] and [2]. Inevitably, most of the patients develop tumour resistance to the first rTKI therapy and therefore require further sequential therapy.

Based on a phase 3 trial, everolimus (EV) is an efficacious treatment option after failure of vascular endothelial growth factor receptor (VEGFr) targeted therapy, particularly rTKI treatment [3]. Current guidelines for the treatment of mRCC have adopted EV as the treatment of choice after VEGF failure [4] and [5]. However, some limited evidence suggests that following failure of one VEGFr targeted agent, patients may still have the potential to respond to another VEGFr inhibitor. Particularly rTKIs such as Sun and sorafenib (Sor) have been applied in sequence, although the data of a phase 2 study suggested limited efficacy of this sequencing regimen [6]. Largely retrospective data form the basis for the sequential use of Sun and Sor or vice versa [7], [8], [9], [10], [11], and [12]. However, studies sufficiently comparing different sequence options are still lacking.

In the context of insufficient comparative data on the best sequence of targeted treatments in mRCC patients, we collected the data of patients treated with two common sequence options: rTKI therapy followed by EV (rTKI-EV) versus rTKI therapy followed by another rTKI (rTKI-rTKI) in two treatment centres. The aim of our retrospective study was to compare these sequence options in terms of efficacy and toxicity.

2. Patients and methods

We retrospectively reviewed patients treated with first rTKI therapy (Sun or Sor) at two large academic centres between 2005 and 2010. Patients receiving the sequence rTKI-EV or rTKI-rTKI were included in this study. Either Sun or Sor was allowed as first rTKI treatments, so the rTKI-rTKI sequence subgroup included patients treated with Sun-Sor or vice versa, and the rTKI-EV subgroup included Sun-EV or Sor-EV. Further therapy lines were individualised and included EV, temsirolimus, dovitinib, interferon α, or bevacizumab plus interferon α. Immunotherapy was the only therapy allowed prior to rTKI treatment and was not considered as a targeted therapy line. Sun was administered daily either as 50mg orally over 4 wk followed by a 2-wk washout period. Stepwise dose reductions by 12.5mg were allowed in case of toxicity. Sor was administered continuously at a full dose of 400mg orally twice a day with allowed dose reduction by 200mg. Dosing for EV was 10mg daily (dose reductions to 5mg daily). All agents were given until progression, death, or intolerable toxicity. Response assessment by computed tomography (CT) or magnetic resonance imaging (MRI) scans was done every 10–12 wk according to the standard Response Evaluation Criteria in Solid Tumours (v.1.0) [13]. Toxicity was graded according to the Common Toxicity Criteria for Adverse Events (CTCAE).

2.1. Statistics

Associations between main characteristics (age, gender, Memorial Sloan-Kettering Cancer Centre [MSKCC] risk [14], and Eastern Cooperative Oncology Group performance group) and response to treatment were explored using the chi-square test and the Mann-Whitney U test as appropriate. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Cox proportional hazards models were applied to explore predictors of PFS, sequential treatment duration, and OS in univariate- and multivariable-adjusted analyses. Predictors of OS and PFS were further tested in stratified Kaplan-Meier analyses whenever appropriate. A p value<0.05 was considered statistically significant. All statistical calculations were performed using SPSS v.18 (IBM Corp, Somers, NY, USA).

3. Results

3.1. Patient characteristics

A total of 108 patients with first rTKI treatment were included in the study. Of these 46 received the rTKI-rTKI sequence, and 62 individuals received the rTKI-EV sequence. The rTKI-rTKI group included Sun-Sor (n=35) and Sor-Sun (n=11); the rTKI-EV group consisted of Sun-EV (n=50) and Sor-EV (n=12). All patients underwent nephrectomy before targeted therapy. Table 1 depicts the main patient characteristics of the study population and by sequence group. There were no statistical significant differences between the two treatment groups (rTKI-rTKI vs rTKI-EV) in terms of main characteristics. However, the number of cases with missing MSKCC risk group was higher among the rTKI-rTKI group. Most patients received Sun as the first rTKI therapy (rTKI-rTKI, 76%; rTKI-EV, 80.6%; p=0.638); the remaining patients were treated with Sor.

Table 1 Patient characteristics




p value*
Age (first targeted therapy), yr, median (IQR) 61.8 (54.5–69.2) 60.7 (53.9–67.2) 62.1 (54.9–69.9) 0.452
Sex, n (%) Female 31 (28.7) 12 (26) 19 (30.6) 0.671
Male 77 (71.3) 34 (74) 43 (69.4)
MSKCC, n (%) Good 18 (16.7) 5 (10.9) 13 (21.0) 0.89
Intermediate 49 (45.4) 16 (34.8) 33 (53.2)
Poor 3 (2.8) 1 (2.2) 2 (3.2)
Unknown 38 (35.2) 24 (52.2) 14 (22.6) 0.002
ECOG, n (%) 0 78 (72.2) 34 (73.9) 44 (70.9)
1 15 (13.9) 4 (8.6) 11 (17.7) 0.294
2 1 (0.9) 0 (0) 1 (1.6)
Unknown 14 (13) 8 (17.4) 6 (9.6)
Histology, n (%) Clear cell 94 (87) 37 (80.4) 57 (91.9)
Non–clear cell 11 (10.2) 6 (13.0) 5 (8.0) 0.071
Unknown 3 (2.8) 3 (6.5) 0 (0)
T stage, n (%) T1 15 (13.9) 8 (17.4) 7 (11.3) 0.519
T2 21 (19.4) 10 (21.7) 11 (17.7)
T3 65 (60.2) 24 (52.2) 41 (66.1)
Unknown 7 (6.5) 4 (8.7) 3 (4.8)
Grade, n (%) G1 6 (5.6) 1 (2.2) 5 (8.1) 0.520
G2 61 (56.5) 25 (54.3) 36 (58.1)
G3 31 (28.7) 15 (32.6) 16 (25.8)
Unknown 10 (9.2) 5 (10.9) 5 (8.0)
Lymph node status, n (%) N0 49 (45.4) 21 (45.7) 28 (45.2) 0.876
N1 9 (8.3) 5 (10.9) 4 (6.5)
N2 7 (6.5) 3 (6.5) 4 (6.5)
NX 43 (39.8) 17 (36.9) 26 (41.9)
Metastases at nephrectomy, n (%) M0 36 (33.3) 13 (28.2) 23 (37.0) 0.358
M1 40 (37.0) 16 (34.7) 24 (38.7)
MX 32 (29.2) 17 (37.0) 15 (24.2)
Metastases at first line ≥3 organ sites 52 (48.1) 21 (45.6) 31 (50.0) 0.700
Bone metastasis 27 (25.0) 10 (21.7) 17 (27.4) 0.654
Liver metastasis 21 (19.4) 9 (19.5) 12 (19.3) 1.000
Metastases at second line ≥3 organ sites 67 (62.0) 29 (63.0) 38 (61.2) 1.000
Bone metastasis 34 (31.4) 16 (34.7) 18 (29.0) 0.537
Liver metastasis 25 (23.1) 7 (15.2) 18 (29.0) 0.110
Previous immunotherapy 59 (54.6) 25 (54.3) 34 (54.8) 1.000

* The p values refer to the chi-square test except for comparisons of median age (Mann-Whitney U test).

rTKI=receptor tyrosine kinase inhibitor; EV=everolimus; IQR=interquartile range; MSKCC=Memorial Sloan-Kettering Cancer Center; ECOG=Eastern Cooperative Oncology Group.

3.2. Treatment efficacy

Table 2 provides the data on response assessment. For the first-line rTKI treatment, the objective response rate did not differ significantly by sequence group, whereas disease control rate (CR plus PR plus SD) was significantly lower for the rTKI-rTKI group (56%) than for the rTKI-EV (82%; p=0.005). Consequently, a higher proportion of primary rTKI resistance (best response progressive disease) was encountered in the rTKI-rTKI group (26%) than in the rTKI-EV group (13%; p=0.04). PFS on first-line rTKI was 6.6 mo (rTKI-rTKI group) and 10.6 mo (rTKI-EV; p=0.06). Upon exclusion of patients with primary rTKI resistance, PFS differences were no longer evident among the sequence groups (11.2 mo vs 11.5 mo).

Table 2 Treatment characteristics and response rate according to sequential targeted therapy




p value
First-line rTKI agent, n (%) Sunitinib 85 (78.7) 35 (76.0) 50 (80.6) 0.638*
Sorafenib 23 (21.3) 11 (23.9) 12 (19.3)
Response First line, n (%) PD 20 (18.5) 12 (26.1) 8 (12.9) 0.019*
SD 50 (46.3) 19 (41.3) 31 (50.0)
PR 22 (20.4) 7 (15.2) 15 (24.1)
CR 5 (4.6) 0 (0) 5 (8.0)
NE 11 (10.2) 8 (17.4) 3 (4.8)
Response Second line, n (%) PD 44 (40.7) 19 (41.3) 25 (40.3) 0.161*
SD 45 (41.6) 15 (32.6) 30 (48.3)
PR 7 (6.5) 5 (10.8) 2 (3.2)
NE 11 (10.2) 7 (15.2) 5 (8.1)
Disease control rate, n (%) First line 77 (71.3) 26 (56.5) 51 (82.3) 0.005*
Second line 52 (48.1) 20 (43.5) 32 (51.6) 0.441*
None 31 (28.7) 9 (19.6) 22 (35.5)
Further treatment lines 1 43 (39.8) 20 (43.4) 23 (37.0) 0.196*
≥2 34 (31.5) 17 (36.9) 17 (27.4)

* Chi-square test/Fisher exact test.

rTKI=receptor tyrosine kinase inhibitor; EV=everolimus; PD=progressive disease; SD=stable disease; PR=partial response; CR=complete response; NE=nonevaluable.

Second-line targeted therapy with either another rTKI or EV appeared to be equally efficacious with a median PFS of 4.0 mo for rTKI and 3.6 mo for EV (p=0.455; Fig. 1). Data on treatment duration and OS are displayed in Table 3. Treatment duration for the entire sequence was 11.0 mo (rTKI-rTKI) and 18.5 mo (rTKI-EV; p=0.051). The median time from diagnosis to treatment was 21.0 mo (95% confidence interval [CI], 17.7–24.3) for rTKI-rTKI and 20.0 mo (10.7–29.3) for rTKI-EV (p=0.766). Interestingly, we observed a statistically significant difference in median OS since first rTKI by sequence group (Table 3 and Fig. 2). After exclusion of all patients with intrinsic rTKI resistance, this difference was still obvious but lost statistical significance (32.2 mo [CI, 23.0–41.4] vs 45.4 mo [CI, 36.7–54.1]; p=0.128). Sensitivity analyses excluding all cases with Sor at first line revealed longer sequence therapy duration and longer OS for the Sun-EV sequence than for the Sun-Sor sequence (Table 3).


Fig. 1 Kaplan Meier estimates of progression-free survival on second-line targeted therapy.EV=everolimus; rTKI=receptor tyrosine kinase inhibitor.

Table 3 Progression-free survival and overall survival according to sequential targeted therapy

All (n=108), mo (95% CI) rTKI-rTKI (n=46), mo (95% CI) rTKI-EV (n=62), mo (95% CI) p value*
PFS, first rTKI 8.3 (5.2–11.2) 6.6 (2.6–10.6) 10.6 (7.4–13.8) 0.058
Sun 7.8 (5.4–10.2) 5.5 (2.4–8.5) 10.6 (7.1–14.1) 0.009
Sor 10.5 (4.7–16.3) 10.5 (5.3–15.7) 13.3 (1.7–24.8) 0.019
PFS, second line 4.0 (2.9–5.1) 4.0 (3.2–4.9) 3.6 (1.8–5.4) 0.455
Sun, first rTKI 4.0 (2.7–5.3) 4.1 (3.4–4.8) 3.3 (2.2–4.3) 0.193
Sequence therapy duration 14.6 (11.4–17.9) 11.0 (6.6–15.3) 18.5 (14.2–22.8) 0.051
Sun, first rTKI 14.1 (12.5–15.7) 10.8 (6.2–15.5) 16.3 (11.7–20.9) 0.001
OS 35.5 (29.0–42.0) 29.0 (18.6–39.5) 43.0 (33.9–52.1) 0.034
Sun, first rTKI 32.7 (24.3–41.2) 22.9 (18.4–27.3) 39.9 (31.5–48.3) 0.008

* The p values refer to the log-rank test.

Restricted to 86 patients who received the Sun-Sor (n=35) or Sun-EV sequence (n=51).

Overall survival calculated from start of first targeted therapy.

CI=confidence interval; rTKI=receptor tyrosine kinase inhibitor; EV=everolimus; PFS=progression-free survival; Sun=sunitinib; Sor=sorafenib; OS=overall survival.


Fig. 2 Kaplan-Meier estimates of overall survival since start of first targeted rTKI (receptor tyrosine kinase inhibitor) therapy.EV=everolimus.

An additional subgroup analysis of the rTKI-rTKI sequence group revealed a longer first-line PFS (10.5 vs 5.5 mo; p=0.067), a longer second line PFS (9.1 vs 4.1 mo; p=0.014), a longer sequence therapy duration (21.0 vs 10.8 mo; p=0.013), and a longer OS (43.0 vs 28.7 mo; p=0.036) for the Sor-Sun sequence compared with the Sun-Sor sequence.

3.3. Toxicity

For the sequential treatment groups (rTKI vs EV), no statistically significant differences were observed in the rate of grade 3 or 4 toxicities (CTCAE 3.0) or the rate of toxicity-induced treatment termination (Table 4). Most toxicity-related side effects were manageable, and permanent dose reductions were necessary in 12 patients (26%) of the rTKI group and 4 patients (6%) of the EV group (p=0.006). Toxicity data mirror the known toxicity profile of rTKI and EV, respectively.

Table 4 Toxicity (common terminology criteria for adverse events grade 3 or 4) and toxicity-related termination of targeted therapy


n=46 n (%)

n=62 n (%)
p value
Treatment termination, first-line rTKI 11 (23.9) 9 (14.5) 0.061*
Second line 6 (13.0) 8 (12.9) 0.773*
Grade 3 or 4 toxicity (second line)
All 9 (19.5) 19 (30.6) 0.397*
Diarrhoea 2 (4.3)
Anaemia 2 (4.3) 2 (3.1)
Mucositis/stomatitis 1 (2.1) 2 (3.1)
Fatigue 1 (2.1) 2 (3.1)
Cachexia 1 (2.1)
Sepsis 1 (2.1)
Elevated γGT 1 (2.1)
Hyperglycaemia 4 (6.4)
Hyperlipidaemia 2 (3.1)
Pneumonitis 1 (1.6)
Renal failure 2 (3.1)
Exanthaema 1 (1.6)
Nausea 1 (1.6)
Thrombosis 1 (1.6)
Stroke 1 (1.6)

* Chi-square test/Fisher exact test.

rTKI=receptor tyrosine kinase inhibitor; EV=everolimus; γGT=γ glutamyltransferase.

3.4. Univariate- and multivariable-adjusted Cox regression models

Table 5 depicts the univariate and multivariable Cox regression models for predictors of PFS (second-line targeted therapy) and OS from the start of sequence targeted therapy. Main characteristics such as MSKCC risk group (or missing data on MSKCC risk) and prior immunotherapy were not associated with PFS or OS. Toxicity (grade 3 or 4) of sequential therapy was a predictor of PFS (hazard ratio [HR]: 1.80; 95% CI, 1.11–2.92; p=0.017) in the univariate analysis underlining the need for stringent patient management. In our exploratory analysis, primary resistance to first rTKI was an independent predictor of second-line PFS (HR: 1.79; 95% CI, 1.15–3.62; p=0.015) and OS (HR: 6.54; 95% CI, 3.01–14.20; p<0.001). Inferior sequence treatment duration (combined PFS first and second targeted treatment line) was related to primary intrinsic rTKI resistance (HR: 3.32; 95% CI, 1.80–5.14). Moreover, Sun as first-line rTKI was independently associated with treatment duration (HR: 2.42; 95% CI, 1.32–4.44; p=0.004) but not with second-line PFS. Interestingly, first-line Sun was independently associated with adverse OS (Table 5).

Table 5 Predictors of progression-free survival on second-line targeted therapy and overall survival

PFS Univariate Cox regression Multivariable Cox regression
HR (95% CI) p value HR (95% CI) p value
Sunitinib (first rTKI) 1.71 (1.02–2.85) 0.038 1.34 (0.72–2.49) 0.352
Primary rTKI resistance (first rTKI) 1.86 (1.12–3.08) 0.016 1.79 (1.15–3.62) 0.015
Sequence rTKI-rTKI (vs rTKI-EV) 1.16 (0.78–1.74) 0.447
Grade 3 or 4 toxicity (second line) 1.80 (1.11–2.92) 0.017 1.63 (0.96–2.77) 0.072
Sunitinib (first rTKI) 2.38 (1.12–5.06) 0.023 2.84 (1.22–6.60) 0.015
Primary rTKI resistance (first rTKI) 4.86 (2.48–9.50) <0.001 6.54 (3.01–14.20) <0.001
Sequence rTKI-rTKI (vs rTKI-EV) 1.75 (1.03–2.96) 0.036 1.27 (0.69–2.34) 0.451
Grade 3 or 4 toxicity (second line) 0.79 (0.42–1.51) 0.479
Primary resistance (second line) 1.81 (1.03–3.19) 0.039 1.67 (0.92–3.03) 0.090

* Overall survival since start of targeted sequence therapy.

PFS=progression-free survival; HR=hazard ratio; CI=confidence interval; rTKI=receptor tyrosine kinase inhibitor; EV=everolimus; OS=overall survival.

4. Discussion

Despite significant improvements in the efficacy of systemic treatment of mRCC patients, the best strategy of sequencing targeted therapies remains a matter of debate. Literally all patients with mRCC inevitably experience tumour progression during first-line treatment necessitating sequential therapy.

In this study we compared frequent sequence strategies. Our data support the notion that both efficacy and safety of the most frequently applied sequential targeted therapies (ie, switching rTKI agents or rTKI followed by EV) may be comparable. Interestingly, however, we observed a significant difference in OS favouring the rTKI-EV sequence option. Given the higher proportion of patients with primary (intrinsic) resistance in the rTKI-rTKI group, selection bias cannot be excluded as a reason for this observation. However, a trend towards improved survival for rTKI-EV was still present upon exclusion of cases with intrinsic rTKI resistance, indicating a potential benefit of an early change of mode of action. Results were confirmed in an analysis restricted to cases with Sun as first rTKI (ie, comparing the Sun-EV sequence and the Sun-Sor sequence).

Prospective data on the best sequential therapy among the available sequence options in mRCC are still lacking. In contrast to our observations, Vickers et al. reported that patients receiving another VEGFr-targeted therapy in the sequence setting may experience a longer PFS compared with those treated with mammalian target of rapamycin (mTOR) inhibitors [15]. However, among the 216 patients, only 24 individuals were treated with mTOR inhibitors, and as few as 3 received EV. Apart from our study, no data exist directly comparing the use of EV and rTKI treatment after failure of first-line rTKI therapy in a relevant number of patients. A prospective phase 2 study reported a median PFS of 4.4 mo and an OS of 16 mo for Sor after failure of Sun or bevacizumab [9]. In a recent study on sequential targeted therapy, a median second-line PFS of 4 mo was reported for 25 patients receiving EV after Sun failure [16]. Although the PFS observed in these studies compares well with our data, OS was usually not reported for the entire sequence of treatments. In line with our study, a number of smaller retrospective trials suggested that the sequential use of Sor and Sun or vice versa may show clinical benefit in mRCC patients [8] and [12], although the only prospective single-arm trial on this sequence option indicated a low efficacy of Sor in the second-line setting [6]. Nonetheless, sequencing VEGFr targeted therapy may be a valid treatment option. Porta et al. recently reported on a multicentre series of 189 patients treated with Sun followed by Sor and vice versa [17]. In this study a longer median duration of sequential therapy was observed for the Sor-Sun sequence. However, the imbalance of important characteristics such as the higher proportion of previous systemic therapy (71% vs 38%) and poor risk patients (32% vs 10%) in the Sun-Sor group may account for this observation. Indeed, another study on registry data did not observe differences in PFS or OS by rTKI sequence [18]. Due to their retrospective nature, the validity of these studies and our observations is limited. In our study, an exploratory subgroup analysis, a trend towards longer PFS and OS estimates was observed for the Sor-Sun sequence compared with the Sun-Sor sequence, but the sample size was too small, and no valid conclusions can be made. Results of ongoing prospective randomised trials comparing sequence options, such as Sun followed by EV versus vice versa (NCT00903174) or Sor versus Tem after failure of Sun (NCT 00474786), are eagerly awaited.

Our study has important limitations. The limited numbers of patients in each group underline the uncertainty of our observations. Due to the fact that some patients were treated outside our centres during first-line therapy, data on MSKCC risk group were missing in a significant number of patients. The imbalanced distribution of relevant variables, such as number of metastatic sites or histologic type and missing data on MSKCC prognostic group, may be additional sources of bias. We cannot exclude a selection bias towards good risk patients due to the relatively high proportion of cytokine-pretreated patients. A novel risk prognosis score has been introduced based on patient data from the targeted therapy era [19] but has not yet been validated. This score cannot be calculated in our patient population because neutrophil count is largely missing.

A number of other factors, such as haemoglobin level, age, brain metastasis, or time from diagnosis to treatment, have an impact on PFS and OS in patients undergoing sequential rTKI treatment [7]. In univariate analyses, significant treatment-related toxicity was associated with inferior PFS in our patients, underscoring the importance of stringent management of adverse events [20] and [21].

A better understanding of the mechanism underlying treatment resistance in mRCC patients will help optimise the treatment strategy. Evasive or acquired tumour resistance may develop via mechanisms like alternative proangiogenic signalling pathways within the tumour, recruitment of bone marrow–derived proangiogenic cells, increased protection of tumour vasculature by pericytes, and increased tumour cell invasiveness to escape oxygen and nutrient deprivation [22]. A countermeasure to overcome acquired tumour resistance could be targeting a different signalling pathway [23], blocking the underlying escape signalling pathway [24], or rechallenging the tumour after restoration of a susceptible tumour microenvironment [25]. Intrinsic (primary) resistance may indicate other as yet undefined pathways. The underlying mechanisms of intrinsic and acquired tumour resistance are complex, and further research is needed.

In our exploratory analysis, first-line Sun treatment was an independent predictor of inferior OS. This observation deserves further study. Sun as a potent antiangiogenic agent may indeed induce an aggressive tumour phenotype [26], [27], and [28], although this hypothesis awaits further confirmation in clinical and translational studies. Intrinsic resistance to first rTKI treatment was a strong independent predictor of OS in our study population. As a consequence, patients with intrinsic rTKI resistance had a low chance of clinical benefit from sequential therapy. These facts underscore that overcoming treatment resistance in mRCC patients (eg, by the development of novel targeting strategies) is key for improving survival perspectives. Upon exclusion of patients with intrinsic rTKI resistance, OS still tended to be longer in the rTKI-EV sequence group. This supports the hypothesis that an early change of mode of action may increase the efficacy of mRCC treatment. However, the switch from VEGFr-targeted therapy to mTOR inhibition may not be sufficient, and targeting of pathways not related to angiogenesis may be necessary to significantly increase treatment efficacy.

5. Conclusions

EV remains the preferred option in rTKI-resistant mRCC according to the evidence available to date. Sequential rTKI therapy with Sun or Sor may provide similar efficacy in terms of PFS and response rate. The trend towards superior OS for the rTKI-EV sequence needs further confirmation in prospective randomised trials. Results from such trials comparing different sequence options are urgently needed to better define the treatment algorithms in rTKI-resistant disease.

Author contributions: Steffen Weikert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Busch, Seidel, Grünwald, Weikert.

Acquisition of data: Busch, Seidel, Wolff, Kempkensteffen, Johannsen, Hinz, Magheli.

Analysis and interpretation of data: Busch, Seidel, Grünwald, Weikert.

Drafting of the manuscript: Busch, Seidel, Grünwald, Weikert.

Critical revision of the manuscript for important intellectual content: Busch, Seidel, Wolff, Kempkensteffen, Johannsen, Hinz, Magheli, Miller, Grünwald, Weikert.

Statistical analysis: Busch, Weikert.

Obtaining funding: None.

Administrative, technical, or material support: Weikert, Miller, Wolff, Grünwald.

Supervision: Weikert, Miller, Magheli, Kempkensteffen, Grünwald.

Other (specify): None.

Financial disclosures: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Manfred Johannsen has received honoraria from Pfizer Germany, Bayer Ag, Novartis Germany, Sanofi-Aventis, Wyeth Germany, Glaxo Smith Kline, and Roche Germany. He is a consultant for Novartis Germany, Glaxo Smith Kline, and Pfizer Germany. Kurt Miller is an advisor to Pfizer, Roche, and Novartis. Steffen Weikert is an advisor to Pfizer, Bayer, and Novartis. The other authors have nothing to disclose.

Funding/Support and role of the sponsor: None.


  • [1] E.J. Mills, B. Rachlis, C. O’Regan, L. Thabane, D. Perri. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer. 2009;9:34 Crossref.
  • [2] J.S. Thompson Coon, Z. Liu, M. Hoyle, et al. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer. 2009;101:238-243 Crossref.
  • [3] R.J. Motzer, B. Escudier, S. Oudard, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456 Crossref.
  • [4] B. Ljungberg, N.C. Cowan, D.C. Hanbury, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58:398-406 Abstract, Full-text, PDF, Crossref.
  • [5] R.J. Motzer, N. Agarwal, C. Beard, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009;7:618-630
  • [6] G. Di Lorenzo, G. Carteni, R. Autorino, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol. 2009;27:4469-4474 Crossref.
  • [7] Elfiky AA, Cho DC, McDermott DF, et al. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol. In press. DOI:10.1016/j.urolonc.2010.01.008.
  • [8] C. Eichelberg, R. Heuer, F.K. Chun, et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol. 2008;54:1373-1378 Abstract, Full-text, PDF, Crossref.
  • [9] J.A. Garcia, T.E. Hutson, P. Elson, et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer. 2010;116:5383-5390 Crossref.
  • [10] M.P. Sablin, S. Negrier, A. Ravaud, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182:29-34 discussion 34 Crossref.
  • [11] A.Z. Dudek, J. Zolnierek, A. Dham, B.R. Lindgren, C. Szczylik. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115:61-67 Crossref.
  • [12] E. Herrmann, N. Marschner, M.O. Grimm, et al. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol. 2011;29:361-366 Crossref.
  • [13] P. Therasse, S.G. Arbuck, E.A. Eisenhauer, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216 Crossref.
  • [14] R.J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, J. Ferrara. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540
  • [15] M.M. Vickers, T.K. Choueiri, M. Rogers, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology. 2010;76:430-434 Crossref.
  • [16] G. Di Lorenzo, C. Buonerba, P. Federico, et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol. 2010;58:906-911 Abstract, Full-text, PDF, Crossref.
  • [17] Porta C, Procopio G, Carteni G, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. In press. DOI:10.1111/j.1464-410X.2011.10186.x.
  • [18] Buchler T, Klapka R, Melichar B, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry. Ann Oncol. In press.
  • [19] D.Y. Heng, W. Xie, M.M. Regan, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794-5799 Crossref.
  • [20] G. Di Lorenzo, C. Porta, J. Bellmunt, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011;59:526-540 Abstract, Full-text, PDF, Crossref.
  • [21] N. Bhojani, C. Jeldres, J.-J. Patard, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53:917-930 Abstract, Full-text, PDF, Crossref.
  • [22] G. Bergers, D. Hanahan. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592-603 Crossref.
  • [23] T.E. Hutson, R.M. Bukowski, C.L. Cowey, R. Figlin, B. Escudier, C.N. Sternberg. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2010;77:48-62
  • [24] G.R. Hudes. Targeting mTOR in renal cell carcinoma. Cancer. 2009;115(Suppl):2313-2320 Crossref.
  • [25] I.N. Zama, T.E. Hutson, P. Elson, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 2010;116:5400-5406 Crossref.
  • [26] S. Loges, M. Mazzone, P. Hohensinner, P. Carmeliet. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. 2009;15:167-170 Crossref.
  • [27] J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, R.S. Kerbel. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232-239 Crossref.
  • [28] M. Paez-Ribes, E. Allen, J. Hudock, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-231 Crossref.


a Department of Urology, Charité University Medicine Berlin, Berlin, Germany

b Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

lowast Corresponding author. Charité University Medicine Berlin, Department of Urology, Charité Platz 1, 10117 Berlin, Germany. Tel. +4930450515052.

Both authors contributed equally to this work.